bioMérieux, Inc., 100 Rodolphe Street, Durham, NC, 27712, USA.
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1719-26. doi: 10.1007/s10096-012-1641-7. Epub 2012 Jun 8.
The identification and/or prediction of the antimicrobial resistance of microorganisms in clinical materials solely by molecular means in the diagnostic microbiology laboratory is not novel. However, the ability to sequence multitudes of bacterial genomes and deliver and interpret the resultant sequence information in near "real-time" is the basis of next-generation sequencing (NGS) technologies. There have been numerous applications and successes of NGS applications in the clinical and public health domain. However, none have, as yet, delivered perhaps the most sought after application, i.e., the generation of microbial sequence data for "real-time" patient management. In this review, we discuss the use of NGS and whole-genome sequencing (WGS) of microorganisms as a logical next step for the routine diagnosis of infection and the prediction of antimicrobial susceptibility in the clinical microbiology laboratory.
临床标本中微生物的抗菌药物耐药性的鉴定和/或预测仅通过分子手段在诊断微生物学实验室中并不新颖。然而，能够对大量细菌基因组进行测序，并近乎实时地提供和解释所得序列信息，这是下一代测序（NGS）技术的基础。NGS 技术在临床和公共卫生领域已经有了许多应用和成功案例。然而，到目前为止，还没有一种方法能够实现最受期待的应用，即生成用于“实时”患者管理的微生物序列数据。在这篇综述中，我们讨论了将 NGS 和微生物全基因组测序（WGS）用作临床微生物学实验室中感染常规诊断和抗菌药物敏感性预测的合乎逻辑的下一步。
